These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35314257)

  • 1. Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
    Anker SD; Sander LE; Fitchett DH; Zinman B; Pernille Ofstad A; Wanner C; Vedin O; Lauer S; Verma S; Yaggi HK; Inzucchi SE
    Diabetes Res Clin Pract; 2022 Apr; 186():109837. PubMed ID: 35314257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
    Ji Q; Ji L; Mu Y; Zhao J; Zinman B; Wanner C; George JT; Zwiener I; Ueki K; Yokote K; Ogawa W; Johansen OE
    Diabetes Obes Metab; 2021 Aug; 23(8):1886-1891. PubMed ID: 33950573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
    Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
    Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
    Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
    Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
    Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
    Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
    Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F
    J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
    Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
    Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
    Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
    Fitchett D; Inzucchi SE; Zinman B; Wanner C; Schumacher M; Schmoor C; Ohneberg K; Ofstad AP; Salsali A; George JT; Hantel S; Bluhmki E; Lachin JM; Zannad F
    ESC Heart Fail; 2021 Dec; 8(6):4517-4527. PubMed ID: 34605192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
    Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
    Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
    J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
    Neeland IJ; Eliasson B; Kasai T; Marx N; Zinman B; Inzucchi SE; Wanner C; Zwiener I; Wojeck BS; Yaggi HK; Johansen OE;
    Diabetes Care; 2020 Dec; 43(12):3007-3015. PubMed ID: 33004464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
    Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
    J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.